Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

58.35
+0.51120.88%
Volume:7K
Turnover:420.75K
Market Cap:97.44M
PE:- -
High:58.48
Open:58.48
Low:58.28
Close:57.84
52wk High:64.60
52wk Low:39.32
Shares:1.67M
Float Shares:1.67M
Volume Ratio:1.05
T/O Rate:0.43%
Dividend:0.71
Dividend Rate:1.21%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Sep 15

Merck & Co Exec Says Potential 340B and Policy Evolutions Would Create Tailwinds but are not Material to the Business - Morgan Stanley Conf

THOMSON REUTERS
·
Sep 15

Merck & Co Exec Says Timing for Raising the $70 Bln Forecast is "to be Determined" Adds "It's Coming"

THOMSON REUTERS
·
Sep 15

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
Sep 15

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Sep 15

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Sep 15

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Sep 15

UnitedHealth Earnings Growth Outlook Unlikely to Change, UBS Says

MT Newswires Live
·
Sep 14

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

Evercore ISI Remains a Buy on UnitedHealth (UNH)

TIPRANKS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14